Skeletal Myoblast Transplantation in Ischemic Heart Failure

DOI Web Site 被引用文献4件
  • Albert A. Hagège
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Jean-Pierre Marolleau
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Jean-Thomas Vilquin
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Armelle Alhéritière
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Séverine Peyrard
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Denis Duboc
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Eric Abergel
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Emmanuel Messas
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Elie Mousseaux
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Ketty Schwartz
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Michel Desnos
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...
  • Philippe Menasché
    From Université Paris-Descartes (A.A.H., A.A., E.A., E.M., E. Mousseaux, M.D., P.M), Faculté de Médecine; INSERM U 633, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Departments of Cardiology, Imaging and Cardiovascular Surgery, Paris, France; Assistance Publique Hôpitaux de Paris (J.-P.M.), Hôpital Saint-Louis, Cell therapy laboratory, Paris, France; INSERM U 582 (J.-T.V., K.S.), Institut de Myologie, Paris, France; INSERM (S.P.), Clinical Investigation Center...

書誌事項

タイトル別名
  • Long-Term Follow-Up of the First Phase I Cohort of Patients

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Skeletal myoblast (SM) transplantation (Tx) in a post-myocardial infarction (MI) scar experimentally improves left ventricular (LV) ejection fraction (EF). Short-term follow-up (FU) studies have suggested that a similar benefit could clinically occur despite an increased risk of LV arrhythmias. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> We report the long-term FU of the first worldwide cohort of grafted patients (n =9, 61.8±11.6 years, previous MI, EF ≤35%) operated on (autologous SM Tx and bypass surgery) in 2000 to 2001 and evaluated before Tx, at 1 month (M1) and at a median FU of 52 (18 to 58) months after Tx (37 patient-years). NYHA class improved from 2.5±0.5 to 1.8±0.4 at M1 ( <jats:italic>P</jats:italic> =0.004 versus baseline) and 1.7±0.5 at FU ( <jats:italic>P</jats:italic> =not significant versus M1; <jats:italic>P</jats:italic> =0.0007 versus baseline). EF increased from 24.3±4% to 31±4.1% at M1 (+28%, <jats:italic>P</jats:italic> =0.001 versus baseline) and remained stable thereafter (28.7±8.1%, +18% versus baseline). There were 5 hospitalizations for heart failure in 3 patients at 28.6±9.9 months, allowing implant in 2 patients with a resynchronization pacemaker. An automatic cardiac defibrillator (ACD) was implanted in 5 patients for nonsustained (n =1) or sustained (n =4) ventricular tachycardia at 12.2±18.6 (1 to 45) months. Despite a beta-blocker/amiodarone combination therapy, there were 14 appropriate shocks for 3 arrhythmic storms in 3 patients at 6, 7, and 18 months after ACD implantation. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> In this cohort of severe heart failure patients both clinical status and EF stably improve over time with a strikingly low incidence of hospitalizations for heart failure (0.13/patient-years) and the arrhythmic risk can be controlled by medical therapy and/or on-request ACD implantation. </jats:p>

収録刊行物

  • Circulation

    Circulation 114 (1_supplement), I108-, 2006-07-04

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ